Welcome to LookChem.com Sign In|Join Free

CAS

  • or

52406-23-2

Post Buying Request

52406-23-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

52406-23-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 52406-23-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,4,0 and 6 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 52406-23:
(7*5)+(6*2)+(5*4)+(4*0)+(3*6)+(2*2)+(1*3)=92
92 % 10 = 2
So 52406-23-2 is a valid CAS Registry Number.

52406-23-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-(4-oxopentanoyloxy)ethyl 4-oxopentanoate

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:52406-23-2 SDS

52406-23-2Downstream Products

52406-23-2Relevant articles and documents

Acyl acid derivative and preparation method and medical application thereof

-

Paragraph 0410-0412, (2020/07/02)

The invention relates to an acyl acid derivative as well as a preparation method and medical application thereof. Specifically, the invention relates to a compound represented by a general formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, and the invention also relates to a use thereof as an active ingredient in the prevention and/or treatment of muscle atrophy-related diseases, including myogenic muscle atrophy, disuse muscle atrophy, senile muscle atrophy, neurogenic muscle atrophy, and a use in the prevention and/or treatment of obesity, fatty liver, cardiovascular and cerebrovascular diseases, metabolic diseases, and anti-aging, wherein the definition of each group in the general formula (I) is the same as the definition in the specification.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 52406-23-2